News und Analysen
![Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Agilent Technologies Inc. (NYSE: A) today announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and
![Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine
![Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
![GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China
GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug
![Relay Medical und Fio Corporation verlängern ihre Absichtserklärung bezüglich der Zusammenarbeit im Hinblick auf eine Schnelltest-Diagnoseplattform](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Relay Medical und Fio Corporation verlängern ihre Absichtserklärung bezüglich der Zusammenarbeit im Hinblick auf eine Schnelltest-Diagnoseplattform
16. August 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) berichten gemeinsam, dass die Unternehmen ihre am
![Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform
August 16, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) jointly report that the Companies have extended the me
![Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
![QIAGEN wird erfolgreiche Wachstumsstrategie mit Fokus auf Umsetzung und mehr Wertschöpfung weiterverfolgen, nachdem das freiwillige öffentliche Übernahmeangebot von Thermo Fisher gescheitert ist](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
QIAGEN wird erfolgreiche Wachstumsstrategie mit Fokus auf Umsetzung und mehr Wertschöpfung weiterverfolgen, nachdem das freiwillige öffentliche Übernahmeangebot von Thermo Fisher gescheitert ist
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, seine erfolgreiche Wachstumsstrategie mit dem Ziel einer deutlichen Wertsteigerung für Aktionäre und andere
![QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other
![Novocure Announces Expansion of Its Executive Leadership Team](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Novocure Announces Expansion of Its Executive Leadership Team
Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the
![Dexcom Appoints Karen Dahut to Board of Directors](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
![Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
![Evotec: Weiter auf Wachstumskurs](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Evotec: Weiter auf Wachstumskurs
Am Dienstag vermeldete Evotec (WKN: 566480) einen neuen Partner-Deal mit Resolute Therapeutics und CARB-X im Bereich Infektionskrankheiten und antimikrobielle Resistenzen. Heute schiebt der
![IMV Inc. Announces Second Quarter 2020 Financial Results](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
IMV Inc. Announces Second Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
![NeutriSci Provides Update Regarding Product Launch in California](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NeutriSci Provides Update Regarding Product Launch in California
Vancouver, British Columbia – August 12, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
![NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien
Vancouver, British Columbia – 12. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
![Premier, Inc. Eliminates Dual-Class Structure to Simplify Ownership; Amends and Extends Group Purchasing Agreements with Member-Owners to Support Sustainable, Long-Term Revenue Growth](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Premier, Inc. Eliminates Dual-Class Structure to Simplify Ownership; Amends and Extends Group Purchasing Agreements with Member-Owners to Support Sustainable, Long-Term Revenue Growth
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has completed a corporate restructuring to eliminate its dual-class ownership structure, through an
![Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent
![Premier, Inc. Initiates Quarterly Cash Dividend and Declares Initial Dividend](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier, Inc. Initiates Quarterly Cash Dividend and Declares Initial Dividend
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share, or $0.76 on an
![THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
- Orphan Drug Designation (ODD) is a status that provides seven years of additional post-approval protection and exemption from filing fees
- Rare Pediatric Disease Designation (RPDD) qualifies the
![Epigenomics: Aktie knallt nach Studiennews – so geht es weiter!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Epigenomics: Aktie knallt nach Studiennews – so geht es weiter!
Neue medizinische Erkenntnisse sorgen für frischen Schwung im Handel mit Epigenomics-Aktien (WKN: A11QW5). Die Ergebnisse der im "Journal of the National Cancer Institute" (JNCI) erschienenen Studie
![Pfenex mit +109% in 3 Monaten: Nächster Buyout für den NBC!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfenex mit +109% in 3 Monaten: Nächster Buyout für den NBC!
Mit Pfenex (WKN: A118RA) meldet die Mai-Empfehlung des No Brainer Clubs ein lukratives Übernahmeangebot. NBC-Mitglieder liegen damit in nur drei Monaten mindestens +109% vorne.
Anfang Mai empfahlen